COMPANY

Flare Therapeutics

HQ: Cambridge, MA source · flaretx.com ↗ · New England

1 open job · last seen Oct 23, 2026 · 6 sources

Keywords: small molecule oncology Metastatic Castration Resistant Prostate Cancer mCRPC mCRPC (Metastatic Castration-resistant Prostate Cancer) Prostatic Neoplasms Castration-Resistant Prostatic Neoplasms mCRPC or Advanced/Metastatic Solid Tumors mCRPC, Metastatic Castration Resistant Prostate Cancer Neoplasms Prostate Neoplasms of Prostate Advanced Urothelial Carcinoma Oral Drug Administration FX-111 FX-909

Profile checked Oct 10, 2026

Since the raise (Jun 30, 2026): 1 of 1 open job was first seen after it.

1Open jobs $85.0MRaised (2 yrs)2Trials (company is sponsor)

Hiring

Title	Location (from posting)	Employer posted	First seen
Don't see an opening for you? Apply anyways!	Cambridge, Massachusetts	May 12, 2021	Oct 8, 2026

See all 1 job

Raises and deals from press releases

Raise Series C · $85M · announced Jun 30, 2026 Company release ↗
Source quote
- Jun 30, 2026 · Company release ↗
  “Flare Therapeutics Secures $85M in Insider-Led Series C Financing and Appoints Anna Protopapas as Chief Executive Officer”
Deal Merck deal · amount not disclosed · announced Oct 21, 2025 Company release ↗
Source quote
- Oct 21, 2025 · Company release ↗
  “Flare Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate FX-909 in Combination with KEYTRUDA ® (pembrolizumab) in New Cohort of Ongoing Phase 1 Trial in Metastatic Urothelial Cancer”
Deal Roche deal · $70M upfront · announced Nov 12, 2024 Company release ↗
Source quote
- Nov 12, 2024 · Company release ↗
  “Flare Therapeutics to receive US $70 million upfront, and potential milestone payments exceeding US$1”

Raises announced in these releases: $85M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Oct 8, 2026 Board tracked Radar started tracking this company’s job board (1 open job at last check). source ↗
Jul 1, 2026 Trial start Phase 1: A Study in Patients With Metastatic Castration-Resistant Prostate Cancer source ↗
Jun 30, 2026 Raise Private equity round — Series C: $85M (total, as published), announced Jun 30, 2026. Source: company's own press page. source ↗
Jun 30, 2026 Raise Series C · $85M source ↗
Oct 21, 2025 Partnership Partnership / licensing announced Oct 21, 2025. Source: company's own press page. source ↗
Nov 12, 2024 Partnership Partnership / licensing announced Nov 12, 2024. Source: company's own press page. source ↗
Aug 24, 2023 Trial start Phase 1: A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma source ↗

Upcoming milestones

Oct 30, 2027 (ESTIMATED) · Phase 1 · A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma · NCT05929235
Feb 15, 2028 (ESTIMATED) · Phase 1 · A Study in Patients With Metastatic Castration-Resistant Prostate Cancer · NCT07719361

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 1

Title	Location (from posting, not HQ)	Employer posted	First seen	Level
Don't see an opening for you? Apply anyways!	Cambridge, Massachusetts	May 12, 2021	Oct 8, 2026	Not stated

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Funding

Raised: $85.0M. Last 2 years.

Jun 30, 2026 Private equity round — Series C: $85M (total, as published), announced Jun 30, 2026. Source: company's own press page. source ↗
Oct 21, 2025 Partnership / licensing announced Oct 21, 2025. Source: company's own press page. source ↗
Nov 12, 2024 Partnership / licensing announced Nov 12, 2024. Source: company's own press page. source ↗

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT07719361	A Study in Patients With Metastatic Castration-Resistant Prostate Cancer	Phase 1	Recruiting	Jul 1, 2026	Feb 15, 2028 (estimated)
NCT05929235	A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma	Phase 1	Active, not recruiting	Aug 24, 2023	Oct 30, 2027 (estimated)

Connect

See your connections at Flare Therapeutics on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18